Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Lagricel Ofteno Multidose vs Single Dose in Healthy Subjects
NCT04081610Phase 1Completed
- Sponsor
- Laboratorios Sophia
- Start
- Sep 2019
- Primary completion
- Oct 2019
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lagricel ofteno in dry eye syndrome (DED) (2 arms), sponsored by Laboratorios Sophia. Primary endpoints: Presence of Adverse Events and Eye Comfort Index at Day 8. Started Sep 2019; status: completed.
02
Drugs
lagricel ofteno
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT04081610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04081610.